Evidence map›Paper›PMID 38881433›Full record

ArticleAddiction (Abingdon, England)2024

Commentary on Darke et al.: Expanded psychedelic access requires new safety monitoring systems.

P Todd Korthuis, Adrianne R Wilson-Poe, Joshua C Black, Andrew Monte

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

P Todd KorthuisDepartment of Medicine, Division of General Internal Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, Oregon, USA.ORCID 0000-0001-5556-3597
Adrianne R Wilson-PoeLegacy Research Institute, Portland, Oregon, USA.
Joshua C BlackRocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, Colorado, USA.ORCID 0000-0002-7329-2740
Andrew MonteRocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, Colorado, USA.

Funding

Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Peer Engagement in Methamphetamine Harm-Reduction with Contingency Management (PEER-CM)R01DA057670 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI Philip Todd Korthuis · 2022 to 2026
$3.3M
Personalizing EmerGency/Acute therapeuticS Utilizing Systems biology (PEGASUS-2)R35GM152157 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI Andrew Albert Monte · 2024 to 2026
$1.2M
NIDA NIH HHS R01 DA057670NIDA NIH HHS R01DA057670NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1DA015815NIGMS NIH HHS R35 GM152157NIGMS NIH HHS R35GM152157SAMHSA HHS 75S20123P00003SAMHSA HHS SAM318573U.S. Food and Drug Administration 75F40122C00165
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HallucinogensHumansHallucinogensdeathharm reductionlysergic acid diethylamide (LSD)psilocybinpsychedelic epidemiologypsychedelic toxicity

Identifiers

PMID38881433
PMCPMC11342452

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.